Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), drawn from the whole corpus: 17 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
9 medicines on record are linked to one of the types below rather than to Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) itself. Grouped by the type that holds them; each list opens that type's own page.
Diagnosis takes years because early disease mimics eczema.
No cure without transplant.
Quality of life with itch and visible disease is under-measured in trials.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
The diagnosis depends on a correlation between the biopsy and the clinical course, and that correlation is only as good as the access to a dermatologist who sees these conditions often. Most people with early mycosis fungoides are managed for years before anybody makes it.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Over-treatment is the commonest harm in this family. Combination chemotherapy produces short remissions and real damage in conditions that are otherwise controlled for decades.
The two aggressive entities in the family are individually so rare that their treatment rests on case series, and they are easy to mistake for the indolent ones at first.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome
Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy
Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.
A milestone in how this cancer is treated.
Topical treatment of mycosis fungoides-type CTCL (Ledaga)